


Committee on Energy and Commerce  
U.S. House of Representatives

Witness Disclosure Requirement "Truth in Testimony"  
Required by House Rule XI, Clause 2(g)(5)

1. Your Name:	<i>Jonathan S. Reiner, MD</i>				
2. Your Title:	<i>Professor of Medicine</i>				
3. The Entity(ies) You are Representing:	<i>Georgetown University</i>				
4. Are you testifying on behalf of the Federal, or a State or local government entity?	<table border="1"><tr><td>Yes</td><td>No</td></tr><tr><td></td><td><input checked="" type="checkbox"/></td></tr></table>	Yes	No		<input checked="" type="checkbox"/>
Yes	No				
	<input checked="" type="checkbox"/>				
5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2013. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.	<i>None</i>				
6. Please attach your curriculum vitae to your completed disclosure form.					

Signature



Date:

*12-7-15*

## CURRICULUM VITAE

### 1) Personal Data

Name	Jonathan Samuel Reiner, MD
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

### 2) Education

#### a) Undergraduate Education

University of Pennsylvania, Bachelor of Arts in Biology  
1977 - 1981

#### b) Graduate/Medical Education

Georgetown University, Master of Science in Physiology  
1981 - 1982

Georgetown University, Doctor of Medicine  
1982 - 1986

#### c) Post-Graduate Training

Internship and Residency:

Cornell University Medical College/North Shore University Hospital, Internal Medicine  
1986 - 1989

Chief Resident in Medicine:

Cornell University Medical College/North Shore University Hospital  
1989 - 1990

Fellowship:

George Washington University Medical Center, Cardiology  
1990 - 1993

George Washington University Medical Center, Interventional Cardiology  
1993 – 1994

3) Employment

Senior Clinical Associate, Cornell University Medical College  
1989 - 1990

Assistant Adjunct Professor of Medicine, George Washington University  
1993 - 1994

Assistant Professor of Medicine, George Washington University  
1994 – 1999

Associate Professor of Medicine, George Washington University  
1999 – 2005

Professor of Medicine, George Washington University  
2005 - Present

4) **Professional Registrations, Licenses, Certifications**

Medical Licensure:  
District of Columbia

Board Certification:  
National Board of Medical Examiners, 1987  
American Board of Internal Medicine, 1989  
Cardiovascular Disease, 1993, 2004  
Interventional Cardiology, 1999, 2011

5) **Societies and Honors**

Recipient of the Squibb/Society for Cardiac Angiography and Intervention Fellowship  
for Research in Cardiac Imaging  
1992 – 1993

George Washington University Subspecialty Faculty Award  
2005

Alpha Omega Alpha Medical Honor Society  
2005

## 6) **Administrative Duties & University Activities**

### a) Departmental

Associate Director, Cardiac Catheterization Laboratory, 1995 - 1997

Director, Cardiac Catheterization Laboratory, 1998 - Present

### b) SMHS/Hospital/MFA Committees

Member, Medical Faculty Senate, 1997 – 2002

Member, Clinical Case Review Committee, 1997-1998

Member, Corporate Compliance Committee, 1998

Member, Radiation Safety Committee, 2000- 2014

Member, Cardiovascular Steering Committee, 2002 – Present

Chairman, MFA Strategic Planning Task Force, 2004

Chairman, Cardiac Catheterization Committee, 2004 - present

## 7) **Educational Achievements**

### Educational Awards:

George Washington University Subspecialty Faculty Award presented by the Internal Medicine Housestaff, 1995

Director, Interventional Cardiology Training Program 1998 – present

Teach 2<sup>nd</sup> year medical school cardiology section 1996 – present

Teach 4<sup>th</sup> year medical school pharmacology elective 1998 – present

Teach 4<sup>th</sup> year medical school emergency medicine section with Dr. James Scott 1998 – present.

## 8) **Consultant Appointments**

None

## 9) **Grants Awarded or Pending**

### a) Grants

Principal Investigator

“Relationship of Lesion Geometry to Phasic Coronary Flow in an Animal Model of Intermediate Coronary Stenoses”, funded by a \$25,000 grant from Squibb Corporation.

1992-1993

Principal Investigator

Hematoma and Vascular Outcome Complication Study (HAVOC). Study of vascular complications following catheterization/angioplasty. Funded by a \$25,000 grant from Boehringer Mannheim Corporation.

1994-1995

b) Clinical Research

Co-Principal Investigator

Evaluation of Doppler Parameters During PTCA (ENDPT). Multicenter trial of patients undergoing PTCA examining whether pre- and post-PTCA intracoronary Doppler flow measurements can be used to predict clinical outcome and restenosis.

1994

Principal Investigator

“Bedside Monitoring of Heparin Anticoagulation”. Clinical study compared activated clotting time determination with the activated partial thromboplastin time using a novel, portable device

1991 - 1992

Principal Investigator

“Enoxaparin in Unstable Angina (ESSENCE) Trial.”

1994-1996

Investigator

“Plasminogen Activator Angioplasty Compatibility Trial (PACT)”.

1995-1997

Principal Investigator

“The Effectiveness and Safety of Subcutaneous Enoxaparin Compared to Intravenous Unfractionated Heparin for Patients Presenting with Unstable Angina or Non-Q Wave MI: An International Double-Blind, Randomized, Parallel Group, Multicenter Center (TIMI 11B).”

1997-1998

Principal Investigator

“Antiplatelet Therapy vs Lovenox plus Antiplatelet Therapy for Patients with an Increased Risk of Stent Thrombosis (ATLAST).”

1997

Principal Investigator

“Evaluation of the Dispatch Catheter for Vein Graft Revascularization (EDGE). An International, Multicenter, Pilot Study of Local Drug Delivery with ReoPro or Urokinase in Patients with de Novo Vein Graft Stenoses.”

1997

Principal Investigator

“OPUS-TIMI 16. A Phase III International Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Orfiban in Patients with Unstable Coronary Syndromes.”

1998

Principal Investigator

“PARAGON-B. A randomized, double-blind, placebo-controlled study of Lamifiban (Ro 44-9883) in patients with unstable angina/non-Q wave myocardial infarction.”

1998-1999

Principal Investigator

“A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Angiographic Trial of the Safety and Efficacy of rhuMAB CD18 in Acute Myocardial Infarction”

1999

Principal Investigator

“A to Z” A multicenter, randomized, controlled, double-blind trial to investigate the clinical efficacy and tolerability of early treatment with simvastatin 40mg daily for 30 days, followed by simvastatin 80 mg daily thereafter in tirofiban-treated acute coronary syndrome patients who have been randomized to receive enoxaparin or unfractionated heparin in conjunction with aspirin, and in optimally-treated ST elevation acute coronary syndrome patients.

2000-2001

“STEP-AMI” Phase II, multicenter, randomized, open-label study evaluating the effects of AR-C69931MX on coronary artery patency when given as an adjunct to standard Activase in patients presenting with acute MI.

2000-2001

Principal Investigator

“ASSENT III” A phase IIIb, randomized, open-label trial with 3 parallel groups: full dose TNK-tPA together with heparin sodium, full dose TNK-tPA together with enoxaparin; and half dose TNK-tPA together with abciximab and heparin sodium in patients with acute myocardial infarction.

2000-2001

Principal Investigator

CAMELOT. Comparison of Amlodipine versus Enalapril to Limit Occurrence of Thrombosis

2001-2004

Principal Investigator

“Synergy” A prospective randomized, open-label, multicenter study in high-risk patients presenting with non-ST elevation myocardial infarction (NSTEMI) managed with an

intended, early-invasive treatment strategy randomized to unfractionated heparin or enoxaparin and concomitant antiplatelet therapy.  
2002-2003

Principal Investigator

“PERISCOPE” Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation. A double-blind, randomized, comparator-controlled study in subjects with type 2 diabetes mellitus comparing the effects of pioglitazone HCL versus glimeperide on the rate of progression of coronary atherosclerotic disease as measured by intravascular ultrasound.

2004 – Ongoing

Principal Investigator

SEPIA-PCI. A multinational, randomized double-blind, double dummy, parallel group, dose ranging phase II Study to Evaluate the pharmacodynamics, the safety and tolerability , and the pharmacokinetics of several Intravenous regimens of the factor Xa inhibitor otamixaban (XRP0673) in comparison to intravenous unfractionated heparin in subjects undergoing non-urgent percutaneous coronary intervention.

2005

Principal Investigator

“AMETHYST” The assessment of the Medtronic AVE Interceptor Sahenous Vein Graft Filter System

2004 -Ongoing

Principal Investigator

“Closure I” A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Starflex Septal Closure System versus Best Medical Therapy in Patients with a Stroke and/or Transient Ischemic Attack due to presumed Paradoxical Embolism through a Patent Foramen Ovale.

2003 -2005

Principal Investigator

“TAXUS ATLAS” A multicenter, single-arm study of the TAXUS Liberte-SR stent for the treatment of patients with de novo coronary artery lesions

2004 -2005

Principal Investigator

“CARE” A multicenter comparison of Visipaque 320 and Isovue-370 in Cardiac Angiography in Renally Impaired Patients

2005-2006

Principal Investigator

“APEX-AMI”. Assessment of Pexeluximab in Acute Myocardial Infarction

2005-2006

Principal Investigator

RESPECT

“Randomized Evaluation of Recurrent Stroke comparing PFO Closure to Established Current Standard of Care Treatment”

2007-2011

Principal Investigator

PFO ACCESS

Registry of patients undergoing PFO closure following failure of conventional medical therapy in setting of patent foramen ovale.

2007-2011

Principal Investigator

PLATO

“A Randomized, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes”

2007

Principal Investigator

ARSENAL

“Genotypic and Phenotypic Correlates of Resistance to Antiplatelet Actions of Aspirin in At-Risk Patient Population”. Original research funded by a grant from the Richard B. and Lynne V. Cheney Cardiovascular Institute at George Washington University.

2008-Ongoing

Principal Investigator

CYPHER ELITE

Randomized comparison of Cypher sirolimus eluting stent to Cyper Elite sirolimus eluting stent.

2008-2009

RIVAL

Radial vs Femoral Access for Intervention Study

2010-2011

Principal Investigator

SYMPPLICITY HTN-3

Renal Denervation in Patients with Uncontrolled Hypertension

2012-2013

## 10) Publications

a) Papers in Refereed Journals



1. **Reiner JS**, Furie RA. Cardiac tamponade as an initial manifestation of systemic lupus erythematosus. *J Rheumatol* 1989;16:1127-9.
2. **Reiner JS**, Lundergan CF, Tenner MP, Abraham AA, Ross AM. Ventricular free wall and septal rupture (double rupture): A “pseudocomplication” during post-infarction laser angioplasty. *Cathet Cardiovasc Diag* 1993; 30:147-149.
3. The GUSTO Angiographic Investigators. The Comparative Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary Artery Patency, Ventricular Function, and Survival after Acute Myocardial Infarction. *N Engl J Med* 1993; 329:1615-22.
4. Deychak YA, Segal J, **Reiner JS**, Nachnani S. Doppler guidewire derived coronary flow reserve distal to intermediate stenoses utilized in clinical decision-making regarding interventional therapy. *Am Heart J* 1994; 128:178-181.
5. **Reiner JS**, Coyne KS, Lundergan CF, Ross AM. Bedside Monitoring of Heparin Therapy: Comparison of Activated Clotting Time to Activated Partial Thromboplastin Time. *Cathet Cardiovasc Diag* 1994;32:49-52.
6. **Reiner JS**, Lundergan CF, Boland J, Thompson MA, Py A, van de Brand M, Pilcher GS, Fink CA, Burton JR, Simoons ML, Califf RM, Topol EJ, Ross AM for the GUSTO Investigators. Early Angiography Cannot Predict Coronary Reocclusion; Observations From The GUSTO Angiographic Study. *J Am Coll Cardiol* 1994; 24:1439-44.
7. **Reiner JS**, Ross AM. Routine, Early, Coronary Angiography Following Thrombolysis For Acute Myocardial Infarction. *American Journal of Therapeutics* 1995; 2:136-40.
8. Deychak YA, Segal J, **Reiner JS**, Rohrbeck SC, Thompson MA, Lundergan CF, Ross AM, Wasserman AG. Doppler guidewire flow velocity indexes measured distal to coronary stenoses associated with reversible thallium perfusion defects. *Am Heart J* 1995;129(2):219-27.
9. Barbash GI, **Reiner JS**, White HD, Wilcox RG, Armstrong PW, Sadowski Z, Morris D, Aylward P, Woodlief LH, Topol EJ, Califf RM, Ross AM, for the GUSTO Investigators. Evaluation of the Paradoxical Beneficial Effects of Smoking in Patients Receiving Thrombolytic Therapy For Acute Myocardial Infarction: Mechanism of the “Smoker’s Paradox” from the GUSTO-I Trial, with Angiographic Insights. *J Am Coll Cardiol* 1995; 26:1222-9.
10. **Reiner JS**, Lundergan CF, Fung A, Coyne K, Cho S, Israel N, Kazmierski J, Pilcher G, Smith J, Rohrbeck S, Thompson M, Van de Werf F, Ross AM, for the GUSTO-1 Angiographic Investigators. The Evolution of Early TIMI 2 Flow Following Thrombolysis for Acute Myocardial Infarction. *Circulation* 1996;94:2441-2446.

11. Lesnefsky EJ, Lundergan CF, Hodgson JMcB, Nair R, **Reiner JS**, Greenhouse SW, Ross AM. Increased Left Ventricular Dysfunction in Elderly Patients Despite Successful Thrombolysis: The GUSTO-1 Angiographic Experience. *J Am Coll Cardiol* 1996; 28:331-7.
12. Woodfield SL, Lundergan CF, **Reiner JS**, Greenhouse S, Thompson MA, Rohrbeck SC, Deychak Y, Simoons ML, Califf RM, Topol EJ, Ross AM, for the GUSTO-1 Angiographic Investigators. Angiographic Findings and Outcome in Diabetic Patients Treated with Thrombolytic Therapy for Acute Myocardial Infarction: The GUSTO-1 Experience. *J Am Coll Cardiol* 1996;28:1661-9.
13. Woodfield SL, Lundergan CF, **Reiner JS**, Thompson MA, Rohrbeck SC, Deychak Y, Smith JO, Burton JR, McCarthy WF, Califf RM, White HD, Weaver WD, Topol EJ, Ross AM. Gender and Acute Myocardial Infarction: Is There a Different Response to Thrombolysis? *Am Coll Cardiol* 1997;29:35-42.
14. Lundergan Cf, **Reiner JS**, McCarthy WF, Coyne KS, Califf RM, Ross AM. Clinical Predictors of Early Infarct Related Artery Patency Following Thrombolytic Therapy: Importance of Body Weight, Smoking History, Infarct Related Artery And Choice of Thrombolytic Regimen: The GUSTO-1 Experience. *J Am Coll Cardiol* 1998;32:641-7.
15. Cohen M, Demers C, Gurfinkle EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. *N Engl J Med* 1997;337:447-52.
16. Ross AM, Coyne C, Moreyra E, **Reiner JS**, Greenhouse SW, Walker P, Simoons ML, Draoui Y, Califf RM, Topol EJ, Van de Werf F, Lundergan CF, for the GUSTO-1 Angiographic Investigators. Extended Mortality Benefit of Early Postinfarction Reperfusion. *Circulation* 1998;97:1549-1556.
17. Ross AM, Lundergan CF, Rohrbeck SC, Boyle D, van de Brand M, Buller CH, Holmes DH, **Reiner JS**, and the GUSTO-1 Angiographic Investigators. Rescue Angioplasty Following Failed Thrombolysis; Technical and Clinical Outcomes In a Large Thrombolysis Trial. *J Am Coll Cardiol* 1998;31:1511-7.
18. Birnbaum Y, Wagner GS, Gates K, Criger DA, Sclarovsky S, Siegel RJ, Granger CB, **Reiner JS**, Ross AM. Correlation of Angiographic Findings and Right (V1 to V3) Versus Left (V4 to V6) Precordial ST-segment Depression in Inferior-wall Acute Myocardial Infarction. *Am J Cardiol* 1999;83:143-148.
19. **Reiner JS**, Katz RJ, Wasserman AG. Electron Beam Computed Tomographic Angiography and Three-Dimensional Reconstruction of a Stented Saphenous Vein Graft. *Circulation* 1999;99:e-16.

20. Ross AM, Coyne KS, **Reiner JS**, Greenhouse SW, Fink C, Frey A, Moreyra E, Traboulsi M, Racine N, Riba AL, Thompson MA, Rohrbeck S, Lundergan CF, for the PACT Investigators. A Randomized Trial Comparing Primary Angioplasty With a Strategy of Short-Acting Thrombolysis and Immediate Planned Rescue Angioplasty in Acute Myocardial Infarction: The PACT Trial. *J Am Coll Cardiol* 1999;34:1954-62.
21. Antman EA, McCabe CH, Gurfinkle EP, Turpie AGG, Bernink PJLM, Salein D, de Luna AB, Fox K, Lablanche J-M, Radley D, Prentice J, Braunwald E, for the TIMI 11B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the TIMI 11B trial. *Circulation*. 1999;100:1593-1601.
22. Barsness GW, Buller C, Ohman EM, Schechter E, Pucillo A, Taylor MA, Miller MJ, **Reiner JS**, Churchill D, Chandler AB, Gonzalez M, Smith J, Tommaso C, Berdan L, Wildemann NM, Hasdai D, Holmes DR, for the Evaluation of the Dispatch Catheter for Vein Graft Revascularization (EDGE) Study. *Am Heart J* 2000;139:824-9.
23. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E, for the OPUS-TIMI-16 Investigators. Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) Trial. *Circulation* 2000;102:149-156.
24. Baran KW, Nguyen M, Mckendall GR, Lambrew CT, Dykstra G, Palmeri ST, Gibbons RJ, Borzak S, Sobel BE, Gourlay SG, Rundle AC, Gibson CM, Barron HV, for the LIMIT AMI Investigators. *Circulation* 2001;104:2778-2783.
25. Lundergan CF, Ross AM, McCarthy WF, **Reiner JS**, Boyle D, Fink C, Califf RM, Topol EJ, Simoons ML, Van Den Brand M, Van de Werf, Coyne KS. Predictors of Left Ventricular Function after Acute Myocardial Infarction: Effects of Time to Treatment, Patency, and Body Mass Index: The GUSTO-I Angiographic Experience. *Am Heart J* 2001;142 (1):43-50.
26. Rah BR, Katz RJ, Wasserman AG, **Reiner JS**. Post-Mortem Three-Dimensional Reconstruction of the Entire Coronary Circulation Using Electron Beam Computed Tomography. *Circulation* 2001;104:3168.
27. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. *Lancet*. 2001 Aug 25;358(9282):605-13.
28. Lundergan CF, **Reiner JS**, Ross AM, et al. How long is too long? Association of time delay to successful reperfusion and ventricular function outcome in acute myocardial infarction: the case for thrombolytic therapy before planned angioplasty for acute myocardial infarction. *Am Heart J* 2002;144:456-62.

29. The Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrom events in a Global Organization Network (PARAGON)-B Investigators. Randomized, Placebo-Controlled Trial of Titrated Intravenous Lamifiban for Acute Coronary Syndromes. *Circulation* 2002;105:316-321.
30. The Synergy Trial Investigators. Enoxaparin vs Unfractionated Heparin in High-Risk Patients with Non-ST-Segment Elevation Acute Coronary Syndromes Managed With an Early Invasive Strategy. *JAMA* 2004;292:45-54.
31. Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin vs. unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. *JAMA*. 2004;292:55-64.
32. Petinaux B, Shesser R, Rah B, **Reiner J**. Association of time delay to successful reperfusion and ventricular function outcome in acute myocardial infarction: the case for thrombolytic therapy before planned angioplasty for acute myocardial infarction. *Am J Emerg Med*. 2004;22:318-20.
33. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ for the CAMELOT Investigators. Effect of Antihypertensive Agents on Cardiovascular Events in Patients with Coronary Disease and Normal Blood Pressure. The CAMELOT Study: A Randomized Controlled Trial. *JAMA* 2004;292:2217-2226.
34. Lederman RJ, **Reiner JS**. A contraindication for internal mammary to coronary bypass. *Heart* 2006 Jan;92(1):51.
35. Gutierrez G, Venbrux A, Ignacio E, **Reiner J**, Chawla L, Desai A. The concentration of oxygen, lactate and glucose in the central veins, right heart and pulmonary artery. A study in patients with pulmonary hypertension. *Critical Care* 2007;11:R44.
36. **Reiner JS**. Contrast-Induced Acute Kidney Injury Prevention Targets: What Works and What Doesn't. *J Invasive Cardiology* 2009;21:20B-22B.
37. **Reiner JS**. Contrast Media and Clotting: What is the Evidence? *Catheter Cardiovasc Interv*. 2010 Mar 1;75 Suppl 1:S35-8. Review.
38. Lasala JM, Mehran R, Moses JW, Popma JJ, **Reiner JS**, Sharma SK, Vetrovec GW. Evidence based management of patients undergoing PCI. Conclusion. *Catheter Cardiovasc Interv*. 2010 Mar 1;75 Suppl 1:S43-5.
39. Mohsen A, **Mazhari R**, **Reiner J**. Multimodality imaging to diagnose pulmonary vein stenosis following atrial fibrillation ablation. *J Invasive Cardiol*. 2011 Sep;23(9):E214-5.

40. **Reiner JS**, Solomon AJ, Katz RJ. Shock and Law. *Circulation*, 2011;124(12):1391-4.

41. Fallahi P, Katz R, Toma I, Li R, **Reiner J**, VanHouten K, Carpio L, Marshall L, Lian Y, Bupp S, Fu S, Rickles F, Leitenberg D, Lai Y, Weksler B, Rebling F, Yang Z, McCaffrey TA. Aspirin Insensitive Thrombophilia: Transcript Profiling of Blood Identifies Platelet Abnormalities and HLA Restriction. *Gene* 2013;520(2):131-8.

42. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. *N Engl J Med*. 2013 Mar 21;368(12):1092-100.

#### b) Invited Publications

1. **Reiner JS**, Hsia JA. Adjuncts to thrombolysis for myocardial infarction: Present status and future directions. *Primary Cardiology* 1993;19:44-52.

2. **Reiner JS**, Wasserman AG. The role of thrombolytic therapy for acute myocardial infarction. *Coronary Artery Disease* 1994;5:373-379

3. **Reiner JS**, Ross AM. If thrombolysis fails, what next? *Journal of Critical Illness* 1994;9:227-228.

4. Ohman EM, **Reiner JS**, eds. Advances in Acute Myocardial Infarction. Combining fibrinolysis and GP IIb/IIIa inhibition with coronary intervention. Monograph. 2001.

5. **Reiner JS**, Young JJ, eds. Ideal Treatment for Acute ST-Segment Elevation Myocardial Infarction. Evolving Strategies in Pharmacotherapy and Percutaneous Coronary Intervention. A continuing medical education monograph. 2003.

6. Cannon CP, Peacock WF, **Reiner JS**. Individual Management Protocols for Acute Coronary Syndrome Treatment (IMPACT). Optimal management of the AMI patient. Monograph. 2004.

7. Dusaj R, **Reiner JS**. Iodinated contrast media – A safety review. *US Cardiology* 2009;6:97–100.

8. Dusaj R, **Reiner JS**. Iodinated contrast media – A safety review. *Interventional Cardiology* 2009;4:22–5.

#### c) Books

Cheney RB, **Reiner J**, Cheney EL. *Heart: An American Medical Odyssey*: New York. Scribner; 2013.

#### d) Abstracts

1. **Reiner JS**, Coyne KS, Lundergan CF, Berdeguez CD, Karcher DS, Ross AM. Superiority of bedside partial thromboplastin time to activated clotting time in controlling heparin anticoagulation. *J Am Coll Cardiol* 1993;21:276-A.
2. Deychak YA, Wasserman AG, **Reiner JS**, Rohrbeck SC, Thompson MA, Lundergan CF, Ross AM, Segal J. Doppler Guidewire flow velocity indices measured distal to coronary stenoses; relationship to quantitative angiography and thallium scintigraphy. *J Am Coll Cardiol* 1993;21:455A
3. Deychak YA, Thompson MA, van de Brand M, **Reiner JS**, Coyne KS, Molhoek GP, Pickering E, Rigby D, Ross AM for the GUSTO Investigators. Coronary Collaterals in the GUSTO Angiographic Substudy. *Circulation* 1993; 88:I-159.
4. **Reiner JS**, Lundergan CF, Boland J, Thompson MA, Py A, van de Brand M, Pilcher GS, Fink CA, Burton JR, Ross AM for the GUSTO Investigators. Post Thrombolytic Angiographic Features Do Not Predict Coronary Reocclusion; Observations From The GUSTO Angiographic Study. *Circulation* 1993; 88:I-209.
5. Ross AM, **Reiner JS**, Thompson MA, Aylward P, Cho S, Deychak YA, Lundergan CF for the GUSTO Investigators. Immediate and Follow Up Procedural Outcome of 214 Patients Undergoing Rescue PTCA in The GUSTO Trial: No Effect of the Lytic Agent. *Circulation* 1993;88:I-410.
6. **Reiner JS**, Lundergan CF, Varghese PJ, Israel N, Morris DC, Walker P, Parris TM, Walsh M, Solberg LE, Topol EJ, Ross AM. Complications Following Angioplasty for Failed Thrombolysis in GUSTO: Further Evidence for the “Rescue Right” Syndrome. *J Am Coll Cardiol* 1994;.454A.
7. **Reiner JS**, Lundergan CF, Delcan J, Deychak YA, Cho S, Blaker AM, O’Toole JD, Hodgson JMcB, van de Brand M, Silverman IM, White CJ, Ross AM. Late Infarct Related Artery Opening After Initially Failed Thrombolysis is Common and Improves Left Ventricular Function. *J Am Coll Cardiol* 1994;14A.
8. **Reiner JS**, Lundergan CF, Rohrbeck SC, Krishnaswami K, Castadot M, Perry J, Brown D, Nelson GIC, Ross AM. The Impact on Left Ventricular Function of Coronary Reocclusion After Successful Thrombolysis for Acute Myocardial Infarction. *J Am Coll Cardiol* 1994 ;13A.
9. Kopecky SL, Reeder GS, **Reiner JS**, Lundergan CF, Razavi A, McCormick D, Coyne KS, Jesse R, Ross AM. Resolution of Coronary Thrombus Over Time: A Report from the GUSTO Angiographic Trial. *J Am Coll Cardiol* 1994; 244A.
10. Ross Am, **Reiner JS**, Vahanian A, Schmidt P, Kazmierski J, Thompson CR, Gossman D, Dorchak J, Lundergan. Early Angiographic Predictors of Excess Mortality Risk Following Lytic Therapy for Myocardial Infarction; Observations from GUSTO. *J Am Coll Cardiol* 1994;27A.

11. Segal J, **Reiner JS**, Thompson MA, Brinker JA, Heuser RR, Weiner BH, Ross AM for the Strecker Stent Investigators. Residual Stenosis and MLD Following Coronary Stenting Do Not Predict Restenosis in the Strecker Stent. *J Am Coll Cardiol* 1994;134A.
12. **Reiner JS**, Lundergan CF, Kopecky SL, Hodgson J, Pilcher G, van den Brand M, Fung A, Ross A, for the GUSTO Investigators. Correlates of Mitral Regurgitation following Acute Myocardial Infarction. *Circulation* 1994; 90:I-110.
13. **Reiner JS**, Lundergan CF, Rigby D, Cho S, Thompson MA, Bates ER, P. Besse, Gainey P, Kells C, Dissmann W, Coyne KS, Ross AM, for the GUSTO Investigators. The Quantitative Impact of Prior Myocardial Infarction on Ventricular Function and Mortality in the GUSTO Angiographic Trial. *Circulation* 1994; 90:I-19.
14. Ross AM, **Reiner JS**, Simoons ML, Pickering E, van der Werf F, Lundergan CF for the GUSTO Angiographic Investigators. Compensatory Hyperkinesis: The Ejection Fraction “Equalizer” after MI. *Circulation* 1994; 90:I-386.
15. Lundergan CF, **Reiner JS**, Deychak YA, Parris T, Brown D, Vahanian A, Rios J, Ross AM. Mortality Stratification in Acute MI by Surface ECG. *Circulation* 1994; 90:I-500.
16. Barbash GI, **Reiner JS**, Granger CB, White HD, Lundergan CF, Ross AM. Smoking and Acute Myocardial Infarction Survival: Demographic and Quantitative Angiographic Foundations for the “Smoker’s Paradox”. *Circulation* 1994; 90:I-221.
17. Lundergan CF, **Reiner JS**, Thompson MA, Burton J, Smith J, Ross AM for the GUSTO Investigators. Effect of Gender on Patency, Reocclusion, Global and Regional Ventricular Function in Acute Myocardial Infarction Following Thrombolytic Therapy. *Circulation* 1994; 90:I-502.
18. **Reiner JS**, Lundergan CF, Fung A, Cho S, Israel N, Kazmierski J, Pilcher G, Smith J, Rohrbeck S, Thompson M, Ross AM for the GUSTO Investigators. The Angiographic Fate of Infarct Related Arteries with TIMI 2 Flow Following Thrombolysis for Acute Myocardial Infarction. *J Am Coll Cardiol* 1995 ;60A.
19. Woodfield SL, Lundergan CF, **Reiner JS**, Deychak Y, Thompson M, Califf R, Ross AM for the GUSTO Angiographic Investigators. Angiographic Findings in Diabetics Treated with Thrombolytic Therapy after Acute Myocardial Infarction. *J Am Coll Cardiol* 1995 105A.
20. Ross AM, Cho S, Lundergan CF, **Reiner JS**, Van de Werf F, Coyne K, Califf R, Topol E and the GUSTO Angiographic Investigators. The Survival Advantage of Early Grade 3 Patency After Thrombolysis for Infarction Increases Over Time. *J Am Coll Cardiol* 1995 6A.

21. **Reiner JS**, Lundergan CF, Israel N, Pilcher G, Rohrbeck S, Thompson M, Ross AM for the GUSTO -1 Investigators. Ventriculographic Evolution in MI Patients with Early TIMI 2 Flow; Improving Flow Results in Improving Left Ventricular Function. *Circulation* 1995;92:I-530.
22. Ross AM, Cho S, Lundergan CF, **Reiner JS**, Walker P, Simoons ML, Van de Werf F, Coyne K and the GUSTO Angiographic Investigators. The Survival Advantage of Early Complete Reperfusion (TIMI Grade 3) After Infarction Doubles Between 30 Days and 2 Years. *Circulation* 1995;92:I-718.
23. Lundergan CF, **Reiner JS**, Ross AM, for the GUSTO -1 Investigators. Effect of Body Weight and Time to Treatment on Early Infarct Related Artery Perfusion Status in Acute Myocardial Infarction. *Circulation* 1995;92:I-597.
24. Lundergan CF, **Reiner JS**, Perry JJ, Ross AM, for the GUSTO -1 Investigators. Independent Determinants of Global and Regional Left Ventricular Function One Week Post Thrombolysis for Acute Myocardial Infarction: Primacy of Early Patency. *Circulation* 1995;92:I-461.
25. Lundergan CF, **Reiner JS**, Ross AM. Determinants of 30 Day and 1 Year Mortality In Acute Myocardial Infarction: Benefit of Early Angiography. *J Am Coll Cardiol* 1996;27: 153A.
26. Lundergan CF, **Reiner JS**, Ross AM. Left Ventricular Functional Determinants of 2 Year Mortality Following Acute Myocardial Infarction. *J Am Coll Cardiol* 1996;27:360A.
27. Coyne KS, Walker PL, **Reiner JS**, Draoui YC, Fink CA, Lundergan CF, Ross AM. Cardiac Specific Two-Year Mortality Related to Initial Post-Thrombolytic Flow Grade. *J Am Coll Cardiol* 1996;27:12A.
28. **Reiner JS**, Lundergan CF, Kopecky SL, Topp H, Boyle D, Ross AM. Ineffectiveness of Thrombolysis for Acute MI Following Vein Graft Occlusion. *Circulation* 1996;96:I-570.
29. Lundergan CF, **Reiner JS**, McCarthy WF, Boyle D, Fink C, Ross AM. Mechanism of Survival Advantage of Increasing Body Weight in Acute Myocardial Infarction. *Circulation* 1996;96:I-243.
30. Ross AM, McCarthy WF, Fink CA, Walker PL, **Reiner JS**, Lundergan CF, Coyne KS. Probability of Being Employed 2 Years After Myocardial Infarction. *J Am Coll Cardiol* 1997;29:452A.
31. Ross AM, **Reiner JS**, Coyne KS, Draoui YC, Lundergan CF. Determinants of Long Term Cardiovascular Drug Use After Myocardial Infarction: Does Country Make a Difference? *J Am Coll Cardiol* 1997;29:491A.



32. Coyne KS, Verrier PA, Walker PL, Fink CA, **Reiner JS**, Lundergan CF, Ross AM. The timing and frequency of vascular complications after coronary angiography. *Circulation* 1997;96:I-135.
33. Ross AM, **Reiner JS**, Coyne KS, Fink CA, Moreyra E. Long term mortality benefit of successful early post infarct reperfusion. *Circulation* 1997;96:I-706.
34. Fink CA, **Reiner JS**, Walker PL, Draoui YC, Chiong EB, Frey AJ, Verrier PS, Lundergan CF, Ross AM. The influence of contrast agents on thrombotic events during acute infarct interventions. *Circulation* I-717:1998.
35. Lundergan CF, **Reiner JS**, Coyne KS, Fink C, Frey AJ, Ross AM. Effect of delay of successful reperfusion on ventricular function outcome: The case for prior thrombolytic therapy with PTCA in acute myocardial infarction. *Circulation* I-281:1998.
36. Barsness GW, Buller CE, Ohman EM, Hasdai D, Schechter E, Pucillo AL, Taylor M, Miller MJ, **Reiner JS**, Churchill D, Wildermann N, Holmes DR. Reduced thrombus burden in saphenous vein grafts with abciximab given through a local delivery catheter. *Circulation* I-354:1998.
37. Ross AM, Coyne KS, **Reiner JS**, Traboulsi M, Fung A, Thompson C, Boyle D, Lundergan CF. Very early PTCA of infarct arteries with TIMI 3 flow is associated with improved clinical outcomes. *J Am Coll Cardiol* 403A: 2000.
38. **Reiner JS**, Staniloae CS, Sharma SK, Katholi RE, Moreyra AE, Solomon RJ; Contrast-induced Nephropathy (CIN) in Patients at the Highest Risk: Data from the CARE (Cardiac Angiography in RENally Impaired Patients) Study. *J Am Coll Cardiol* 2008

#### 11) Presentations at National Meetings

1. Superiority of bedside partial thromboplastin time to activated clotting time in controlling heparin anticoagulation. Presented at the 42nd annual Scientific Session of the American College of Cardiology, March 1993, Anaheim, CA.
2. Relationship of lesion geometry to phasic coronary flow in an animal model of intermediate coronary stenoses. Presented at the annual meeting of The Society for Cardiac Angiography and Interventions, May, 1993, San Antonio, TX.
3. Post Thrombolytic Angiographic Features Do Not Predict Coronary Reocclusion; Observations From The GUSTO Angiographic Study. Presented at the 66th Scientific Sessions of the American Heart Association, November, 1993, Atlanta, GA.

4. The Impact on Left Ventricular Function of Coronary Reocclusion After Successful Thrombolysis for Acute Myocardial Infarction. Presented at the 43rd annual Scientific Session of the American College of Cardiology, March 1994, Atlanta, GA.
5. Complications Following Angioplasty for Failed Thrombolysis in GUSTO: Further Evidence for the “Rescue Right” Syndrome. Presented at the 43rd annual Scientific Session of the American College of Cardiology, March 1994, Atlanta, GA.
6. The Quantitative Impact of Prior Myocardial Infarction on Ventricular Function and Mortality in the GUSTO Angiographic Trial. Presented at the 67th Scientific Sessions of the American Heart Association, November, 1994 , Dallas, TX.
7. Correlates of Mitral Regurgitation following Acute Myocardial Infarction. Presented at the 67th Scientific Sessions of the American Heart Association, November, 1994, Dallas, TX.
8. The Angiographic Fate of Infarct Related Arteries with TIMI 2 Flow Following Thrombolysis for Acute Myocardial Infarction. Presented at the 44th annual Scientific Session of the American College of Cardiology, March 1995, New Orleans, LA.
9. Angioplasty, Thrombolysis, or Both. Presented at Cardiovascular Emergencies and More: Pushing the Envelope. Clinician’s Update: 1996 prior to the American College of Emergency Physicians, September 1995, Washington, DC
10. Ventriculographic Evolution in MI Patients with Early TIMI 2 Flow; Improving Flow Results in Improving Left Ventricular Function. Presented at the 68th Scientific Sessions of the American Heart Association, November, 1995, Anaheim, CA.
11. The Fate of TIMI 2 Flow. Presented at the 11th international workshop. Thrombolysis and Interventional Therapy in Acute Myocardial Infarction. Anaheim, CA, November, 1995.
12. Acute Myocardial Infarction: Angioplasty or Thrombolysis? Presented at Critical Care: Treatment of Acute Ischemic Syndromes prior to the 101st Annual Scientific Meeting, National Medical Association, July, 1996, Chicago, IL.
13. Ineffectiveness of Thrombolysis for Acute MI Following Vein Graft Occlusion. Presented at the 69th Scientific Sessions of the American Heart Association, November, 1996, New Orleans, LA.
14. Impact of clopidogrel on patients going to cardiac surgery. Presented at the 1st Annual George Washington University Surgical Critical Care Symposium, April 2004, Arlington, VA.
15. Complex coronary interventions in the DES era. Satellite meeting prior to Transcatheter Cardiovascular Interventions, September, 2004, Washington DC.

16. Regional STEMI systems. The DC experience. Presented at Cardiovascular Research Technologies 2011, Washington, DC.

17. Primary PCI in Non-PCI Hospitals, Debate. Presented at Cardiovascular Research Technologies 2011, Washington, DC

18. Regional STEMI systems. Update on The DC experience. Presented at Cardiovascular Research Technologies 2012, Washington, DC.

## 12) **Service to the Community**

### Restart DC

Raised more than \$400,000 and founded Restart DC a program which has donated over 150 automated external defibrillators in the Washington, DC area to churches, schools, senior citizen centers, boys and girls clubs, The Salvation Army, and all of the District of Columbia Public Libraries. The program has trained hundreds of people in the use of an AED.

### The Cardiac Arrest Survival Act of 2011 (HR 3511)

Drafted legislation which was introduced in the US House of Representatives in December, 2011 which would unify the disparate laws around the United States governing requirements for the use of defibrillators and good Samaritan liability protection for AED owners and rescuers who use AEDs.

### DC EMS Ambulance ECG Transmission

Obtained \$100,000 grant from CTIA-The Wireless Association for acquisition of technology which enables DC EMS to transmit ECGs from ambulances to DC cardiac centers. The wireless modems were gifted to the DC government from the GW Heart and Vascular Institute.